What alternatives to Cosentyx (secukinumab) are used for the same conditions?
Cosentyx (secukinumab) is an IL‑17A inhibitor used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Alternatives are usually other biologics with similar goals (dampening immune signaling) but different targets, so they can be options when a person reports an allergy or hypersensitivity concern with Cosentyx.
Common alternatives include:
- IL‑17 pathway drugs: other IL‑17A/IL‑17 receptor–targeting biologics (these may or may not be acceptable depending on what the reaction was to Cosentyx).
- IL‑12/23 or IL‑23 pathway drugs: biologics that target different cytokines involved in psoriasis and related inflammatory arthritis.
- TNF‑alpha inhibitors: biologics that block TNF, another inflammatory driver in these diseases.
- Conventional systemic therapy (for some patients): methotrexate, cyclosporine, acitretin, or apremilast (for eligible cases), depending on severity and prior treatment.
Because you mentioned allergy concerns, the safest “alternative” depends on the nature of the reaction (rash/hives vs. breathing symptoms vs. anaphylaxis, timing, and whether it happened after each dose).
If the problem is an allergy to Cosentyx, can you switch to another IL‑17 drug?
Sometimes, but it depends on the specific hypersensitivity pattern. If a patient had a true immediate-type allergic reaction or severe hypersensitivity to secukinumab, clinicians often avoid drugs in the same class until the risk is clarified by an allergy specialist.
If the reaction was a non-severe skin reaction or delayed rash, prescribers may consider:
- switching within the IL‑17 class (to a different IL‑17 agent), or
- switching out of the IL‑17 pathway entirely (e.g., to an IL‑23 or TNF inhibitor).
The key question for the prescribing clinician is whether the reaction suggests a class effect (same immune target) or a drug-specific event. This is especially important for reactions involving breathing difficulty, facial swelling, generalized hives, or fainting.
What other biologic options are typically considered for plaque psoriasis?
For plaque psoriasis patients with Cosentyx concerns, prescribers commonly consider agents targeting different immune pathways, such as:
- IL‑23 inhibitors (often used for plaque psoriasis with good skin-clearing results)
- TNF inhibitors (an established psoriasis option, including for those with joint disease)
- IL‑12/23 inhibitors (another pathway option)
Your dermatologist’s choice usually depends on:
- the severity of skin disease and whether it is fast-flaring,
- whether there is psoriatic arthritis,
- prior biologic exposure and response,
- infection history and screening results (especially for TB/hepatitis, which biologics require).
What options are used if you have psoriatic arthritis or ankylosing spondylitis too?
For psoriatic arthritis or ankylosing spondylitis, switching off Cosentyx can follow the same “different immune target” logic:
- TNF inhibitors are widely used for these inflammatory joint conditions.
- IL‑23/IL‑12/23 pathway drugs may be considered depending on the exact diagnosis and treatment history.
- IL‑17 alternatives are sometimes considered when IL‑17 is still considered appropriate and the allergy concern is judged low risk.
A clinician will often weigh how much your joints were helped on Cosentyx and how quickly you need symptom control when switching.
Could the allergy be managed without changing treatment?
In some cases, allergy evaluation can clarify whether:
- it was a true hypersensitivity reaction versus an infusion/injection-site reaction,
- the reaction was mild and possibly manageable,
- or it indicates a higher-risk response that warrants stopping.
Depending on severity, an allergist may recommend testing, timing review, and an approach to rechallenge or avoidance. This decision is individualized and should not be done without the prescriber and allergy specialist.
What should you do next with your prescriber (to get the safest alternative)?
When discussing alternatives, bring details such as:
- the exact symptoms (hives, swelling, rash, wheezing, fever, injection-site reaction),
- how soon they occurred after the dose,
- whether symptoms recurred after subsequent doses,
- your current medications and any infection history.
That information helps determine whether to switch within IL‑17 drugs or move to a different class.
If you share the condition you’re treating (plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis) and what the allergy symptoms were, I can narrow down which Cosentyx alternatives are most commonly used for that situation.
Source
- DrugPatentWatch.com (background on drug and patent context): https://www.drugpatentwatch.com